Stimulation of type 1 and type 8 Ca2+/calmodulin-sensitive adenylyl cyclases by the Gs-coupled 5-hydroxytryptamine subtype 5-HT7A receptor.

The Journal of Biological Chemistry
L P BakerD R Storm

Abstract

The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) plays an important regulatory role in developing and adult nervous systems. With the exception of the 5-HT3 receptor, all of the cloned serotonin receptors belong to the G protein-coupled receptor superfamily. Subtypes 5-HT6 and 5-HT7 couple to stimulation of adenylyl cyclases through Gs and display high affinities for antipsychotic and antidepressant drugs. In the brain, mRNA for 5-HT6 is found at high levels in the hippocampus, striatum, and nucleus accumbens. 5-HT7 mRNA is most abundant in the hippocampus, neocortex, and hypothalamus. To better understand how serotonin might control cAMP levels in the brain, we coexpressed 5-HT6 or 5-HT7A receptors with specific isoforms of adenylyl cyclase in HEK 293 cells. The 5-HT6 receptor functioned as a typical Gs-coupled receptor in that it stimulated AC5, a Gs-sensitive adenylyl cyclase, but not AC1 or AC8, calmodulin (CaM)-stimulated adenylyl cyclases that are not activated by Gs-coupled receptors in vivo. Surprisingly, serotonin activation of 5-HT7A stimulated AC1 and AC8 by increasing intracellular Ca2+. 5-HT also increased intracellular Ca2+ in primary neuron cultures. These data define a novel mechanism for the regulatio...Continue Reading

References

Oct 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·R T PremontR Iyengar
Sep 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·S KatsushikaY Ishikawa
Jan 1, 1992·Journal of Psychoactive Drugs·C M Meston, B B Gorzalka
Nov 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·P G FeinsteinR R Reed
Nov 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·B N Gao, A G Gilman
Feb 1, 1988·Journal of Molecular and Cellular Cardiology·E M Subers, N M Nathanson
Aug 1, 1987·Molecular and Cellular Biology·C Chen, H Okayama
Apr 1, 1974·Analytical Biochemistry·Y SalomonM Rodbell
Oct 13, 1995·The Journal of Biological Chemistry·G A WaymanD R Storm
Jan 6, 1995·The Journal of Biological Chemistry·R Taussig, A G Gilman
Dec 1, 1993·Naunyn-Schmiedeberg's Archives of Pharmacology·N AdhamT A Branchek
Jun 1, 1993·Trends in Pharmacological Sciences·G Milligan
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M RuatJ C Schwartz
Jan 1, 1993·Journal of Neurochemistry·Z XiaD R Storm
Jun 7, 1996·The Journal of Biological Chemistry·R T PremontJ Hanoune
Mar 1, 1996·Psychotherapy and Psychosomatics·B E Leonard
Jan 1, 1996·Annual Review of Pharmacology and Toxicology·R K SunaharaA G Gilman
May 1, 1996·Pharmacology, Biochemistry, and Behavior·F G GraeffJ F Deakin
Jan 1, 1996·Behavioural Brain Research·K J Simansky
Jan 1, 1997·Biological Psychiatry·J C Soares, J J Mann

❮ Previous
Next ❯

Citations

Sep 18, 2013·Experimental Brain Research·Evelien GellynckKathleen Van Craenenbroeck
Apr 26, 2012·Journal of Molecular Neuroscience : MN·Petra EhlingThomas Budde
Mar 23, 2004·European Journal of Pharmacology·Peter B HedlundPascal Bonaventure
Dec 9, 2003·Trends in Molecular Medicine·Diethelm W RichterEvgeni Ponimaskin
Aug 26, 1999·Neuropharmacology·N M Barnes, T Sharp
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Daniel HoyerGraeme R Martin
Mar 28, 2002·Pharmacology & Therapeutics·J R RaymondM N Garnovskaya
Feb 9, 2000·Trends in Pharmacological Sciences·P VanhoenackerJ E Leysen
Apr 27, 2000·Cellular Signalling·Y Chern
Mar 2, 1999·British Journal of Pharmacology·M HemedahF J Mitchelson
Feb 3, 1999·Annals of the New York Academy of Sciences·M W HamblinD E Heidmann
Jun 3, 2000·Annual Review of Pharmacology and Toxicology·T A Branchek, T P Blackburn
Jan 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·P B HedlundJ G Sutcliffe
Jul 12, 2014·Molecular Brain·Matteo GiuliettiBernardo Nardi
Oct 18, 2014·Frontiers in Behavioral Neuroscience·Daria GusevaEvgeni Ponimaskin
Jan 5, 2010·Brain Research·Ignacio MataBenedicto Crespo-Facorro
Mar 19, 2013·European Journal of Pharmacology·Florent ViguierSylvie Bourgoin
Sep 24, 2004·Physiology·Gregory D Ferguson, Daniel R Storm
Sep 1, 2005·Molecular Pharmacology·Pascal Amireault, François Dubé
Feb 28, 2003·Molecular Pharmacology·Hongbing Wang, Daniel R Storm
Jun 11, 2015·British Journal of Pharmacology·I KajiJ D Kaunitz
Jun 18, 2014·CNS Neuroscience & Therapeutics·Vladimir S NaumenkoEvgeni G Ponimaskin
May 7, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Marco IdzkoDavide Ferrari
Dec 31, 2005·The Journal of Pharmacology and Experimental Therapeutics·Melissa A MahgoubLisa M Monteggia
Jan 2, 2020·Molecular Medicine·Alejandro Quintero-Villegas, Sergio Iván Valdés-Ferrer
Feb 9, 2007·Journal of Neurochemistry·Daniel S Cowen
Jan 4, 2018·Doklady. Biochemistry and Biophysics·N V LifantsevaV I Melnikova
Oct 4, 2019·European Journal of Medicinal Chemistry·Sangeetha-Laura ThirumaranChristophe Rochais

❮ Previous
Next ❯

Related Concepts

Related Feeds

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.